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Vitamin D may not only reflect disease but may also serve as a prognostic indicator. Our aim was to assess the gender-specific
utility of vitaminDmeasured as 25-hydroxy-vitaminD [25(OH)D] to predict all-cause and cardiac death in patients with suspected
acute coronary syndrome (ACS) and to compare its prognostic utility to brain natriuretic peptide (BNP) and high-sensitivity C-
reactive protein (hsCRP). Blood samples were harvested on admission in 982 patients. Forty percentwerewomen (65.9± 12.6 years).
Mortality was evaluated in quartiles of 25(OH)D, BNP, and hsCRP, respectively, during a 5-year follow-up, applying univariate and
multivariate analyses. One hundred and seventy-three patients died; 78 were women. In 92 patients (37 women), death was defined
as cardiac. In women, the univariate hazard ratio (HR) for total death of 25(OH)D in Quartile (Q) 2 versus Q1, Q3 versus Q1, and
Q4 versus Q1 was 0.55 (95% CI 0.33–0.93), 0.29 (95% CI 0.15–0.55), and 0.13 (95% CI 0.06–0.32), respectively. In females, it was
an independent predictor of total and cardiac death, whereas BNP and hsCRP were less gender-specific. No gender differences in
25(OH)D were noted in a reference material. Accordingly, vitamin D independently predicts mortality in females with suspected
ACS.
1. Introduction
Cardiovascular disease (CVD) is the primary cause of mor-
tality both in men and women worldwide [1]. Women have
been underrepresented in clinical trials [2]. They very often
present with atypical symptoms and are frequently undi-
agnosed. Furthermore, their risk factors are understudied.
Due to women’s higher age of disease manifestation, they are
also more likely to have other diseases and comorbidities,
rendering the diagnosis more difficult and complex. This has
also resulted in less research related to the predictive utility of
the established biomarkers in this gender.
Recently, numerous observational and epidemiological
studies suggest that vitamin D deficiency may be related to
CVD and mortality [3–9] and is associated with myocardial
infarction (MI) [10, 11] and sudden cardiac death (SCD) [12].
As vitamin D deficiency in men and women is increasing,
we believe that the general diet does not contain a sufficient
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amount of this vitamin and/or that people do not spend
enough time outdoors to create a sufficient amount of this
vitamin upon sun exposure. In a previous study with 2-year
follow-up [13], we found low levels of 25-hydroxy-vitamin
D [25(OH)D] in a chest-pain population from Northern
Argentina. This was an unexpected finding, as we assumed
that our study population would be protected from vitamin
D deficiency due to high sun exposure (latitude 24 degrees
south of the Equator, altitude >1000 meters above sea level).
Vitamin D may add prognostic information in CVD
patients beyond that of the traditional biomarkers consisting
of the troponins, brain natriuretic peptide (BNP), and high-
sensitivity CRP (hsCRP).
The troponins are sensitive biomarkers of myocardial
injury in the acute coronary syndrome (ACS). BNP is released
into the circulation in response to ventricular dilatation and
pressure overload [14, 15] and is a well-known marker of left
ventricular dysfunction and heart failure (HF) [16–19] as well
as a prognostic marker in the ACS [20]. C-reactive protein is
an acute-phase reactant and a marker of underlying systemic
inflammation, including atherosclerosis and plaque rupture
[21–23]. HsCRP assays have been shown to be of prognostic
value in CVD and ACS [20, 24].
The objective of this study was to assess the gender-





) to predict all-cause mortality
and cardiac death as well as SCD during a 5-year follow-
up of a chest-pain population with suspected ACS from
Northern Argentina, employing univariate and multivariate
analyses, and to evaluate its prognostic utility as compared
to BNP and hsCRP. In addition, levels of 25(OH)D in our
patient populations were compared with the 25(OH)D levels
collected from healthy blood donors.
2. Methodology
2.1. Study Design and Patient Population. The details of
the ARgentinean Risk Assessment Registry in the Acute
Coronary Syndrome, the “ARRA-RACS Study” (Ref. Clinical
Trial.gov identifier: NCT01377402), have been published
previously [13, 20]. Briefly, the study was performed at nine
hospitals in the Province of Salta, Northern Argentina. It was
designed to assess the prognostic utility of 25(OH)D, BNP,
and hsCRP levels in 982 consecutive patients, hospitalized
with chest pain and suspected ACS, from December 2005
to January 2009. Furthermore, we collected blood samples
from 104 blood donors (51% females), drawn from the same
locality.
The primary outcome was a 5-year all-cause mortality
from the time of inclusion, and the secondary outcomes
included cardiac death and SCD.The total patient population
was divided into two subgroups, females and males, respec-
tively.
Main exclusion criteria were age <18 years, unwillingness
or incapacity to provide informed consent, and prior inclu-
sion in the present study. Baseline characteristics of the total
population have previously been described [13].
The study was approved by the Ethics Committee at
the Board of Medical School of Salta and by other local
institutions [13] and was conducted in accordance with
the Helsinki Declaration of 1971, as revised in 1983. The
Norwegian biobank containing Argentinean blood samples
was approved by the Regional Board of Research Ethics
and by the Norwegian health authorities. This study was
monitored by Stavanger Health Research, Stavanger, Norway.
Written informed consent was obtained from all patients.
2.2. Blood Samples and Laboratory Measurements. Blood
samples were drawn immediately following admission by
direct venipuncture of an antecubital vein, applying a min-
imum of stasis. A second blood sample for repeated troponin
T (TnT) determination was drawn six hours following the





, TnT, hsCRP, glucose and
lipids in serum, BNP measured in EDTA (ethylenediamine
tetraacetic acid) plasma, and estimated glomerular filtration
rate (eGFR), calculated by the Modification in Diet in Renal
Disease (MDRD) formula.
TnT was quantified by a cardiac-specific second-
generation troponin T ELISA assay from Roche Diagnostics,
using a high-affinity cardiac-specific TnT isoform antibody
[25].The lower detection limit of the assay used is 0.01 ng/mL.
In this study, a cut-off level of 0.05 ng/mL was used with a
coefficient of variation of 10% for the diagnosis of an MI,
whereas patient groups in this study were defined according
to TnT release (TnT > 0.01 ng/mL).
BNP (Microparticle Enzyme Immunoassay Abbott
AxSYM, Abbott Laboratories, Abbott Park, IL, USA) and
hsCRP (Tina-quant C-reactive protein (latex) high sensitive
assay, Roche Diagnostics, Germany) were analyzed as
recommended by the manufacturer and as previously
described [20].
25(OH)D analysis was carried out at the Department of
Medical Biochemistry at the Stavanger University Hospital.
Assessment of 25(OH)D status was performed by the deter-





serum, applying liquid-liquid extraction, derivatization with
4-phenyl-1,2,4-triazoline-3,5-dione reagent (PTAD, Sigma-
Aldrich, St. Louis, MO, USA), followed by liquid chromatog-
raphy coupled with tandem mass spectrometry detection, as
previously described [13].
25(OH)D levels were also analyzed in blood samples
collected from blood donors.
2.3. Statistical Analysis. Patients were divided into quar-
tiles according to their 25(OH)D, BNP, and hsCRP levels,
respectively. Approximately normally distributed variables
were given as mean and standard deviation (SD), while
variables with more skewed distributions were given as
median and quartiles.The Chi-square test for association was
applied between the 25(OH)D, BNP, and hsCRP quartiles,
respectively, and categorical variables at baseline.Theoneway
ANOVA was used to test for the equality of means of scale
variables (e.g., age) amongst the quartiles and the two-sample
𝑡-test and Mann-Whitney tests were used for comparing the
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means and medians, respectively, of two samples. The hazard
ratios (HR) are presented with 95% confidence interval (CI).
Stepwise Cox multivariable proportional hazards regression
models with total death, cardiac death, and SCD, as the
dependent variable, and 25(OH)D, BNP, hsCRP, and other
variables as potential independent predictors (listed below)
were fitted. To examine the differences in prognosis between
subjects in the upper quartiles versus the lowest quartile
of 25(OH)D, BNP, and hsCRP, respectively, we adjusted for
gender, age, smoking, hypertension, index diagnosis, diabetes
mellitus (DM), congestive heart failure (CHF) (defined by
Killip-Kimball class [26] at admission; patients in classes 2
to 4 were classified as CHF patients and patients in class 1
were classified as non-CHF), history of previous coronary
heart disease (CHD) (i.e., history of either angina pectoris,
MI, coronary artery bypass graft (CABG), or percutaneous
coronary intervention (PCI)), hypercholesterolemia/use of
statins, TnT > 0.01 ng/mL, eGFR, hsCRP, BNP, body mass
index (BMI) (kg/m2), month of sampling, and use of beta-
blockers prior to enrolment. The Kaplan-Meier product
limits were used for plotting time-to-event and the logrank
test was used to compare survival curves across quartiles.
The statistical analyses were performed using the statistical
package SPSS version 19.0. All tests were two-sided with a
significance level of 5%. Highly significant differences were
based on a significance level of 1%.
3. Results
A total of 982 patients (588 men and 394 women) were
enrolled in the ARRA-RACS study. Four samples were not
available and two patients were lost to follow-up. At index
hospitalization, 388 patients (39.6%) had a peak TnT exceed-
ing 0.01 ng/mL. Of these, 258 (43.9%) were males and 130
(33.1%) were females.
Mean age of the total population was 62.2 ± 13.4 years.
Mean age for females and males was 65.9 ± 12.7 years
and 59.7 ± 13.3 years, respectively. The median 25(OH)D
concentration in the total population was 50.7 (38.3–62.4)
nM (25 and 75 percentiles), differing in females and males
(Mann-Whitney test; 𝑃 < 0.001); 44.2 (34.0–57.5) nM (25
and 75 percentiles) versus 54.3 (43.0–64.4) nM (25 and 75
percentiles). The median BNP concentration in females and
in males was 81.0 (36.7–199.9) pg/mL (25 and 75 percentiles)
and 74.8 (35.1–168.4) pg/mL (25 and 75 percentiles), respec-
tively, and the median hsCRP concentration was 3.5 (1.6–8.3)
mg/L (25 and 75 percentiles) and 3.0 (1.3–8.8) mg/L (25 and
75 percentiles), respectively.
The distribution of clinical baseline characteristics in the
quartiles of 25(OH)D, BNP, and hsCRP, respectively, for the
total population has previously been described [13, 20].
Baseline characteristics stratified according to 25(OH)D
quartiles at admission in females and males are shown in
Tables 1 and 2, respectively.
After a follow-up period of 5 years, 173 patients (17.6%)
had died, 78 were women and 95 were men. In 92 patients
(9.4%) (37 women and 55men), death was defined as cardiac,
of whom 59 patients (6.0%) (24 women and 35 men) were
characterized as SCD.
3.1. Female Patient Population. In the univariate analysis
(Table 3), there was a statistically significant difference in HR
when comparing each of the upper three quartiles to the
lowest quartile (Q1) of 25(OH)D with respect to all-cause
mortality, cardiac death, and SCD. The HR for total death
of 25(OH)D in Q2 versus Q1, Q3 versus Q1, and Q4 versus
Q1 was 0.55 (95% CI, 0.33–0.93), 𝑃 = 0.027, 0.29 (95% CI,
0.15–0.55), 𝑃 = 0.000, and 0.13 (95% CI, 0.06–0.32), 𝑃 =
0.000, respectively. Comparing the highest quartile (Q4) to
Q1 of BNP, the HR for all-cause mortality, cardiac death,
and SCD was also statistically significant. A similar result
was obtained for all-cause mortality when comparing the
respective quartiles of hsCRP,whereas this biomarkerwas not
found to predict cardiac death.
In the multivariate analysis (Table 3), the HR for all-
cause mortality and cardiac death in Q4 compared to Q1
of 25(OH)D was 0.16 (95% CI, 0.06–0.42), 𝑃 = 0.000, and
0.08 (95% CI, 0.01–0.59), 𝑃 = 0.014, respectively, whereas
25(OH)D status did not add any prognostic information
related to SCD. With regard to BNP, HR for all-cause
mortality in Q4 compared to Q1 was 4.58 (95% CI, 1.56–
13.45), 𝑃 = 0.006, whereas hsCRP yielded no prognostic
information.
The Kaplan-Meier survival plots for the cumulative risk
of all-cause mortality in women in the 25(OH)D quartiles
are presented in Figure 1 (logrank test 𝜒2 (3) = 36.217; 𝑃 <
0.001). The receiver operating characteristics curves (ROCs)
for all-cause mortality related to 25(OH)D, BNP and hsCRP
quartiles, respectively, are presented in Figure 2. The areas
under the ROC for 25(OH)D, BNP, and hsCRP were 0.291
(𝑃 = 0.000), 0.773 (𝑃 = 0.000), and 0.630 (𝑃 = 0.001),
respectively.
3.2. Male Patient Population. In the univariate quartile anal-
ysis (Table 3), results obtained in males, comparing Q4 to
Q1, showed the same pattern as in females, whereas Q2-Q3
differed only slightly compared to Q1.
In the multivariable analysis (Table 3), 25(OH)D status
did not add any prognostic information in males. The HR of
BNP for cardiac death and SCD in Q4 compared to Q1 was
4.22 (95% CI, 1.42–12.58), 𝑃 = 0.010, and 4.55 (95% CI, 1.01–
20.44),𝑃 = 0.048, respectively.TheHRof hsCRP for all-cause
mortality in Q4 compared to Q1 was 2.10 (95% CI, 1.12–3.94),
𝑃 = 0.020.
TheKaplan-Meier survival plots for the cumulative risk of
totalmortality inmen in the 25(OH)Dquartiles are presented
in Figure 3 (logrank test 𝜒2 (3) = 15.704;𝑃 < 0.001).The ROC
curves for all-cause mortality related to 25(OH)D, BNP, and
hsCRP quartiles, respectively, are presented in Figure 4. The
areas under the ROC for 25(OH)D, BNP, and hsCRP were
0.405 (𝑃 = 0.003), 0.650 (𝑃 = 0.000), and 0.638 (𝑃 = 0.000),
respectively.
3.3. Blood Donors. Mean age of the total blood donors group
(𝑛 = 104) was 46.1 ± 10.1 years. There were 53 females with a
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Table 1: Baseline characteristics of female patients arranged according to quartiles of 25(OH)D.
Characteristics 𝑛 (%) Quartiles of 25(OH)D 𝑃 value
Q1 Q2 Q3 Q4
25(OH)D (nM)∗ 27.1 ± 5.3 39.0 ± 2.7 50.7 ± 3.6 68.2 ± 8.4 0.000
Age, years∗ 70.5 ± 11.3 67.8 ± 12.6 64.8 ± 11.9 60.3 ± 12.7 0.000
Smoking status, 𝑛 (%) 0.328
Current smoker, 𝑛 (%) 8 (8.3) 11 (11.3) 15 (15.5) 13 (13.7)
Past smoker, 𝑛 (%) 79 (82.3) 69 (71.1) 73 (75.3) 72 (75.8)
Never smoked, 𝑛 (%) 9 (9.4) 17 (17.5) 9 (9.3) 10 (10.5)
Angina pectoris, 𝑛 (%) 16 (16.3) 21 (21.4) 23 (23.2) 20 (20.4) 0.669
CHF, 𝑛 (%)
Killip class 2–4 24 (24.5) 21 (21.4) 9 (9.1) 17 (17.3) 0.031
History of previous MI, 𝑛 (%) 10 (10.2) 6 (6.1) 4 (4.0) 4 (4.1) 0.230
CABG, 𝑛 (%) 4 (4.1) 4 (4.1) 2 (2.0) 0 (0.0) 0.207
PCI, 𝑛 (%) 7 (7.1) 5 (5.1) 9 (9.1) 7 (7.1) 0.757
Hypertension, 𝑛 (%) 71 (72.4) 71 (72.4) 74 (74.7) 61 (62.2) 0.219
History of DM 1, 𝑛 (%) 2 (2.1) 1 (1.0) 1 (1.0) 0 (0.0) 0.566
History of DM 2, 𝑛 (%) 31 (32.0) 15 (15.5) 15 (15.2) 7 (7.2) 0.000
STEMI, 𝑛 (%) 11 (11.3) 8 (8.5) 12 (12.4) 9 (9.3) 0.804
TnT release, 𝑛 (%) 45 (45.9) 33 (33.7) 24 (24.5) 28 (28.6) 0.009
eGFR (𝜇mol L−1)∗ 74.6 ± 32.7 78.9 ± 30.9 83.3 ± 30.3 77.8 ± 26.2 0.240
Cholesterol†/statin, 𝑛 (%) 18 (18.4) 17 (17.3) 13 (13.1) 19 (19.4) 0.664
Beta-blocker, 𝑛 (%) 21 (21.6) 26 (26.8) 28 (28.3) 25 (26.0) 0.742
Known CHD, 𝑛 (%) 22 (22.7) 30 (30.6) 29 (29.3) 25 (25.8) 0.594
BMI (kg/m2)∗ 28.3 ± 5.2 27.6 ± 5.8 27.9 ± 5.2 27.3 ± 4.1 0.641
BNP quartiles 0.004
Q1 19 (19.4) 16 (16.3) 31 (31.3) 32 (32.7)
Q2 17 (17.3) 25 (25.5) 27 (27.3) 30 (30.6)
Q3 27 (27.6) 27 (27.6) 23 (23.2) 21 (21.4)
Q4 35 (35.7) 30 (30.6) 18 (18.2) 15 (15.3)
hsCRP quartiles 0.062
Q1 21 (21.6) 21 (21.4) 29 (29.3) 25 (25.5)
Q2 21 (21.6) 23 (23.5) 28 (28.3) 27 (27.6)
Q3 18 (18.6) 32 (32.7) 21 (21.2) 27 (27.6)
Q4 37 (38.1) 22 (22.4) 21 (21.2) 19 (19.4)
∗Mean ± SD.
†Concentration > 250mg/dL.
SD: standard deviation; 25(OH)D: 25-hydroxyvitamin D; CHF: congestive heart failure; MI: myocardial infarction; CABG: coronary artery bypass grafting;
PCI: percutaneous coronary intervention; DM: diabetes mellitus; STEMI: ST-elevation myocardial infarction; TnT: troponin T; eGFR: estimated glomerular
filtration rate; CHD: coronary heart disease; BMI: body mass index; BNP: B-type natriuretic peptide; and hsCRP: high-sensitivity C-reactive protein.
mean age of 46.7 ± 9.7 years, BMI of 27.2 ± 4.2 kg/m2, and a
25(OH)D level of 54.5 ± 19.3 nM. The mean age of the male
population (𝑛 = 51) was 45.4 ± 10.4 years, and this gender
presentedwith a BMI of 28.7±4.1 kg/m2 and a 25(OH)D level
of 52.5 ± 14.9 nM. No gender differences in 25(OH)D levels
were found in this normal population.
4. Discussion
In this prospective observational study from Northern
Argentina, in which we address the prognostic utility of
25(OH)D, BNP, and hsCRP during a 5-year follow-up in
patients presenting with chest pain and suspected ACS, we
found that 25(OH)D was independently related to the risk
of death in females and that this risk marker may be of less
importance inmales. BNP and hsCRP behaved as general risk
markers with a slightly different pattern in females andmales.
In a 2-year survival analysis of the same patient material,
25(OH)D deficiency and elevated BNP and hsCRP levels
were associated with reduced survival, both for all-cause
and for cardiac mortality [20] in the total population, even
after correcting for confounders including cardiovascular risk
factors,medication, age, gender, BMI, and sampling time [13].
Females represented 40% of the patient population in the
present study.They were older and had lower 25(OH)D levels
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Table 2: Baseline characteristics of male patients arranged according to quartiles of 25(OH)D.
Characteristics 𝑛 (%) Quartiles of 25(OH)D 𝑃-value
Q1 Q2 Q3 Q4
25(OH)D (nM)∗ 34.3 ± 5.4 48.7 ± 3.1 59.3 ± 2.9 75.3 ± 12.5 0.000
Age, years∗ 65.3 ± 13.0 59.5 ± 13.3 57.1 ± 12.4 56.9 ± 13.0 0.000
Smoking status, 𝑛 (%) 0.891
Current smoker, 𝑛 (%) 53 (37.3) 46 (32.2) 48 (33.1) 43 (29.7)
Past smoker, 𝑛 (%) 55 (38.7) 62 (43.4) 63 (43.4) 63 (43.4)
Never smoked, 𝑛 (%) 34 (23.9) 35 (24.5) 34 (23.4) 39 (26.9)
Angina pectoris, 𝑛 (%) 33 (22.6) 41 (27.9) 39 (26.5) 30 (20.4) 0.414
CHF, 𝑛 (%)
Killip class 2–4 32 (21.9) 16 (10.9) 19 (12.9) 27 (18.4) 0.040
CABG, 𝑛 (%) 10 (7.0) 14 (9.7) 5 (3.4) 8 (5.5) 0.174
PCI, 𝑛 (%) 22 (15.1) 15 (10.2) 17 (11.6) 16 (10.9) 0.581
Hypertension, 𝑛 (%) 102 (69.9) 83 (56.5) 80 (54.4) 91 (61.9) 0.033
History of DM 1, 𝑛 (%) 4 (2.8) 5 (3.4) 2 (1.4) 0 (0.0) 0.138
History of DM 2, 𝑛 (%) 43 (30.3) 35 (24.1) 23 (15.9) 18 (12.4) 0.001
STEMI, 𝑛 (%) 27 (18.9) 21 (14.7) 25 (17.2) 31 (21.2) 0.527
TnT release, 𝑛 (%) 78 (53.4) 56 (38.1) 64 (43.5) 60 (40.8) 0.047
eGFR (𝜇mol L−1)∗ 80.6 ± 33.1 86.5 ± 26.3 85.2 ± 22.3 79.8 ± 25.1 0.089
Cholesterol†/statin, 𝑛 (%) 28 (19.2) 21 (14.3) 22 (15.0) 21 (14.3) 0.606
Beta-blocker, 𝑛 (%) 37 (25.9) 44 (30.3) 37 (25.7) 35 (24.1) 0.661
Known CHD, 𝑛 (%) 56 (38.9) 63 (43.4) 50 (34.2) 49 (33.3) 0.255
BMI (kg/m2)∗ 28.1 ± 4.4 27.9 ± 3.8 29.1 ± 3.8 28.1 ± 3.6 0.057
BNP quartiles 0.014
Q1 34 (23.3) 36 (24.5) 44 (29.9) 33 (22.4)
Q2 29 (19.9) 39 (26.5) 33 (22.4) 45 (30.6)
Q3 29 (19.9) 36 (24.5) 42 (28.6) 40 (27.2)
Q4 54 (37.0) 36 (24.5) 28 (19.0) 29 (19.7)
hsCRP quartiles 0.009
Q1 20 (13.9) 38 (25.9) 42 (28.6) 43 (29.3)
Q2 30 (20.8) 43 (29.3) 36 (24.5) 39 (26.5)
Q3 46 (31.9) 38 (25.9) 31 (21.1) 33 (22.4)
Q4 48 (33.3) 28 (19.0) 38 (25.9) 32 (21.8)
∗Mean ± SD
†Concentration > 250mg/dL.
SD: standard deviation; 25(OH)D: 25-hydroxyvitamin D; CHF: congestive heart failure; MI: myocardial infarction; CABG: coronary artery bypass grafting;
PCI: percutaneous coronary intervention; DM: diabetes mellitus; STEMI: ST-elevation myocardial infarction; TnT: troponin T; eGFR: estimated glomerular
filtration rate; CHD: coronary heart disease; BMI: body mass index; BNP: B-type natriuretic peptide; and hsCRP: high-sensitivity C-reactive protein.
than men. The baseline 25(OH)D quartile characteristics for
men and women were similar, except for hypertension and
hsCRP. Significantly more male patients had hypertension
and higher levels of hsCRP in the lowest quartile of 25(OH)D.
In the BNP and hsCRP quartiles, there were several differ-
ences in the baseline characteristics (not shown). Males with
high BNP presented withmore risk factors for cardiovascular
disease. A similar relationship was found in the hsCRP
quartiles for both genders, especially in women. These data
are in accordance with the current review literature stating
that women present with more multifaceted disease [27, 28].
25(OH)D was found to be an independent predictor for
total and cardiac death in women. BNP was found to be
independently related to all-cause mortality in women and
to cardiac and sudden cardiac death in males.
The gender differences in prognostic utility in relation to
25(OH)D and BNP were not quite as consistent for hsCRP.
This biomarker was found to be an independent predictor of
all-cause mortality limited to the male population.
In our univariate analysis of the prognostic utility of
25(OH)D in women, there was a gradual and statistically
significant increase in predictive utility by a factor of 2
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Table 3: Hazard ratios for 25(OH)D, BNP, and hsCRP in univariate and multivariate analyses in both gender.
Females Males
Univariate HR (95% CI)∗ Multivariate HR (95% CI)∗ Univariate HR (95% CI)∗ Multivariate HR (95% CI)∗
25(OH)D
All-cause mortality 0.13 (0.06–0.32) 0.16 (0.06–0.42) 0.45 (0.26–0.79) 0.70 (0.36–1.34)
Cardiac death 0.04 (0.01–0.31) 0.08 (0.01–0.59) 0.30 (0.13–0.66) 0.38 (0.14–1.06)
Sudden cardiac death 0.06 (0.01–0.46) 0.15 (0.02–1.20) 0.20 (0.07–0.60) 0.29 (0.08–1.03)
BNP
All-cause mortality 9.02 (3.84–21.19) 4.58 (1.56–13.45) 2.86 (1.60–5.09) 1.79 (0.91–3.54)
Cardiac death 12.77 (2.99–54.48) 2.64 (0.57–12.18) 6.04 (2.33–15.68) 4.22 (1.42–12.58)
Sudden cardiac death 7.22 (1.62–32.31) 1.90 (0.31–11.73) 5.87 (1.71–20.16) 4.55 (1.01–20.44)
hsCRP
All-cause mortality 2.43 (1.31–4.48) 1.60 (0.80–3.17) 2.30 (1.31–4.03) 2.10 (1.12–3.94)
Cardiac death 1.97 (0.83–4.71) 0.83 (1.02–1.11) 1.32 (0.65–2.69) 1.08 (0.47–2.48)
Sudden cardiac death 3.07 (0.98–9.65) 1.13 (0.32–4.06) 1.62 (0.66–3.95) 1.40 (0.52–3.81)
25(OH)D: 25-hydroxyvitamin D; BNP: B-type natriuretic peptide; hsCRP: high-sensitivity C-reactive protein; HR: hazard ratio; CI: confidence interval.
∗Highest quartile (Q4) versus lowest quartile (Q1). 25(OH)D, BNP, and hsCRP levels are highest in Q4.






















Figure 1: Kaplan-Meier plots for the cumulative risk of all-cause
mortality in women in the 25(OH)D quartiles.
from the first to second quartile and from the second to
third quartile, respectively, whereas, from the third to fourth
quartile, the total mortality increased by 1.5.This relationship
was not noted in men, in whom the difference was similar
between the first and each of the three upper quartiles.
Our multivariate analysis has demonstrated an abun-
dance of confounding factors related to 25(OH)D in males,
diluting the utility of 25(OH)D as an independent prognostic
indicator in this gender.
The gradual increase in death through the quartiles in
women and the maintenance of predictive utility as judged
by ourmultivariate analysis could be explained by their lower
intraquartile values of 25(OH)D compared to males. The
lower 25(OH)D concentration in women could be due to its
binding to vitamin D receptors in fatty tissue which is more
predominant in the female gender. Another explanation may
be related to the domestic/indoor occupation of women with


















Figure 2: Receiver operating characteristic curves for 25(OH)D,
BNP, and hsCRP for evaluation of all-cause mortality in the female
patient population.
cream and make-up. In addition, women in this study were
five years older than men in the corresponding 25(OH)D
quartiles, and, with a reduction of 7-dehydrocholesterol in the
epidermis and dermis due to age, skin of older individuals
does not convert 25(OH)D as effectively as skin in younger
people [29]. However, as there were no gender differences in
25(OH)D levels in the normal blood donor population, in
which age and BMI were matched, we have to consider the
possibility that 25(OH)D levels may be associated with the
burden of disease.
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Figure 3: Kaplan-Meier plots for the cumulative risk of all-cause


















Figure 4: Receiver operating characteristic curves for 25(OH)D,
BNP, and hsCRP for the evaluation of all-causemortality in themale
patient population.
In the ROC analysis, we demonstrated that 25(OH)D
values are associated with a higher mortality in females
(0.291) compared tomen (0.405) (lowAUC scores in theROC
analysis reflect a higher mortality in the lowest compared to
the highest quartile, and the opposite relationship is found
when the risk is higher in the upper compared to the lowest
quartile).
The main strength of this study is the high proportion
of females (40%), with an evaluation of outcome in both
genders. Moreover, the mortality rate was high, allowing
us to include several covariates in our multivariate model.
Furthermore, only two patients were lost to follow-up.
Limitations include only one blood sample at admission
and levels of 25(OH)D, BNP, and hsCRP before and after
the acute event remain unknown. Although we did not
adjust for left ventricular ejection fraction, we did adjust
for known CHF and CVD as well as for BNP and hsCRP
for the evaluation of the prognostic utility of 25(OH)D.
Furthermore, we did not measure parathyroid hormone.
5. Conclusion
Vitamin D was found to be an independent predictor of
all-cause and cardiac mortality in females but not in males.
Lower values of vitamin D in women in the main study may
reflect a greater health deficiency, as no gender difference was
found in normal subjects.
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